nPL4GBM Clinical validation of NANO-PL: a hydrogel-based formulation of a small molecule for a highly targeted therapy against Glioblastoma Multiforme (GBM)
- Coordinator
- Targtex SA, Portugal
- Runs
- 1 November 2024 to 31 October 2026
- Status
- Running
- EU funding
- €2.5m
- Total cost
- €3.8m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 101144600
What the project is doing
In the project's own words, from its summary on CORDIS.
Glioblastoma (GBM) is considered the highest unmet need in oncology. The average life expectancy of GBM patients is 12-18 months, and the 5-year survival rates remain below 7%. Despite the efforts, the available therapy today counts only with a few (ineffective) approved therapies. Using a machine learning algorithm, we have discovered a correlation between a small molecule and an unexplored target in GBM. We have developed a hydrogel-based formulation of the molecule with great safety and efficacy in vivo.
Our formulation showed 40% long-term survival in a GBM rat model, with complete tumour eradication after a single dose treatment. NANO-PL is a one-time treatment, applied locally during surgery, which is effective even in GBM cells that are resistant to the standard of care or those involved in recurrence. NANO-PL also showed a synergistic efficacy with temozolomide, standard-of-care. The EIC will enable the clinical validation of NANO-PL, completely unlocking the GBM treatment.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Targtex SA | Torres Vedras | Portugal | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI